Maharashtra ready to start Covid-19 vaccination from January if Centre gives approval hindustantimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hindustantimes.com Daily Mail and Mail on Sunday newspapers.
With Covid vaccines being sped up, Modi govt builds mechanism to monitor adverse reactions
India already has an ‘adverse events following immunisation’ or AEFI system for its existing programmes, but Covid vaccination is set to be very different.
Abantika Ghosh 15 December, 2020 8:33 pm IST Text Size:
A+
New Delhi: As India prepares to launch its largest vaccination programme, likely with a Covid-19 vaccine that has only been given expedited approval because of the current pandemic situation, the Government of India has begun to put in place an elaborate mechanism for monitoring adverse events following immunisation (AEFI).
The Covid vaccination programme will be unique also because it will only target adults, and states have been asked to rapidly detect and promptly respond to any AEFIs to ensure public confidence in the new vaccine does not wane.
Covid-19 vaccine rollout to be a huge logistical headache for India indiagazette.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiagazette.com Daily Mail and Mail on Sunday newspapers.
JAMMU: Jammu & Kashmir has shown a record improvement in the last three years in key Maternal and Child health indicators according to the fresh report of National Family Healthy Survey (NFHS-5) conducted by International Institute of Population Sciences, Mumbai.
The report was released on Saturday by Ministry of Health and Family Welfare, GoI for 22 states and union territories.
“If we compare the achievements in key health indicators recorded in National Family Healthy Survey report (NFHS-5) 2019-20 with the NFHS-4 of 2015-16, J&K has recorded 22 points decrease in Neonatal Mortality Rate (NNMR) from 23.1 to 9.8, 16 points decrease in Infant Mortality Rate (IMR) from 32.4 to 16.3 and 19 points decrease in Under Five Mortality Rate (U5MR) from 37.6 to 18.5, which is unprecedented and is the reflection of health status of general population,” said an official handout.
by
As the news of four vaccine candidates claiming high efficacy levels in field trials cheered up the pandemic-struck globe, India, with more than 9 million confirmed Covid-19 cases, and a battered economy, is getting ready to vaccinate a population of more than a billion people, that too, twice. And that too, quite rapidly, for that is believed to be the sure-shot way to arrest the pandemic spread.
No doubt, India, as the world’s leading vaccine manufacturer, is in a better position vis-à-vis many other developing countries for accessing vaccines. Serum Institute of India alone is planning to produce a billion doses of Novavax vaccine by 2021 and Bharat Biotech Ltd is getting ready to produce its own vaccine soon, but challenges galore in the path: distribution logistics, supply of the right vaccine with a proven efficacy level with no accompanying side-effects and cost of the vaccine.